In this study, we aim to investigate the potential for the accumulation and proteolysis of versican to act as a biomarker for immunotherapy response in breast cancer by evaluating the relationship between versican, its proteolysis, and the infiltration of CD8+ tumor-infiltrating lymphocytes. This evidence concerns the gene CD8A and breast carcinoma.